ClinicalTrials.gg
CompletedNCT02663479Updated Mar 13, 2020

Nutraceutical Supplement in the Management of Hypertension

A Phase 1/2 interventional study of Cardiopressin and Placebo in Hypertension, sponsored by Thorne HealthTech, Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-03-13.

Sponsored by Thorne HealthTech, Inc · Phase 1/2, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,032 studies in Hypertension with a site in United States — 268 open to participants now, 369 under way, 16 of them phase 3. Hypertension · United States.

Enrollment
1,254th of 1,780
40 · median 100
Started
2015
with 67 others
Phase 1/2
34 of 2,032
5 open now
Registered
1,029th of 2,032
by date

Among the 2,032 studies in Hypertension with a site in United States, this one is the 1,254th largest by enrollment of the 1,780 interventional ones that give a count, is one of 68 that started in 2015, is one of 34 in phase 1/2, and was the 1,029th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

268 of the 2,032 studies in Hypertension with a site in United States are open now. Recruiting first, the newest first:

263 more — sign in →

All 268 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,032 studies in Hypertension with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of a proprietary nutraceutical supplement in capsule form over 4 months in treating blood pressure in a group of chronic hypertensive subjects that are not receiving any pharmaceutical anti-hypertensive agents or other nutraceutical supplements.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with chronic hypertension: Blood pressure at study entry must be greater than or equal to systolic blood pressure of 140 mm Hg but less than 180 mm Hg or diastolic blood pressure greater than or equal to 90 mm Hg but less than 105 mm Hg
  • Subjects are not taking any prescription anti-hypertensive drugs.
  • Subjects must be off all nutraceutical supplements for at least 30 days prior to entry into the study.

Exclusion criteria

Exclusion Criteria

  • Myocardial infarction, PTCA , stent, CABG within 5 years, known clinical CHD or clinical angina.
  • History of cerebrovascular accident (CVA).
  • Creatinine over 2.5 mg/dL.
  • Known allergy or sensitivity to any components of the study blood pressure supplement.
  • Chronic liver disease with , ALT, alkaline phosphatase over 1.5 x normal lab values.
  • Known cancer within 2 years.
  • Clinical congestive heart failure ( systolic or diastolic CHF)
  • Pregnant and nursing women and women.
  • Women of child bearing age not on approved control.
  • Type 1 and Type 2 diabetes mellitus on medications.
  • If the study subjects develop BP over 180 mm Hg systolic or 110 mm Hg diastolic during the study, they will be discontinued from the study and the investigator will immediately start rescue drug therapy for BP control.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Cardiopressin

    A 5 capsule proprietary blend of herbal extracts and nutrients

    Dietary Supplement: Cardiopressin

  • Placebo comparator
    Placebo

    A 5 capsule placebo matched in color and size to the Experimental supplement

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementCardiopressin
  • Dietary supplementPlacebo
06

What researchers measure

Primary outcomes

  1. Blood Pressure

    Reduction in systolic and diastolic blood pressure as measured by office readings and 24 hour ABM ( ambulatory blood pressure monitor)

    Time frame: 4 months

Secondary outcomes

  1. Endothelial Function

    Measured via Endopat

    Time frame: 4 months

  2. Small arterial compliance

    Measured via computerized arterial pulse wave analysis (CAPWA)

    Time frame: 4 months

  3. Large arterial compliance

    Measured via computerized arterial pulse wave analysis (CAPWA)

    Time frame: 4 months

  4. Central arterial blood pressure

    Measured via computerized arterial pulse wave analysis (CAPWA)

    Time frame: 4 months

07

Study locations

1 site
  • Hypertension Institute of Nashville, TN
    Nashville, Tennessee 37205, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2015, a primary completion of Aug 2017 and a completion of Oct 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2016
First posted
Jan 26, 2016
Start
Sep 2015
Primary completionActual
Aug 2017
CompletionActual
Oct 2017
Last update
Mar 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02663479
Lead sponsor
Thorne HealthTech, Inc
Responsible party
Sponsor
First posted
Jan 26, 2016
Start date
Sep 2015
Primary completion
Aug 2017
Completion
Oct 2017
Last update
Mar 13, 2020

Study contacts

Mark Houston, MD, MS, MSc
principal investigator · Hypertension Institute
Bodi Zhang, MD, MPH, PhD
principal investigator · Thorne Research
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion